Portside Wealth Group LLC Sells 13,652 Shares of Abbott Laboratories $ABT

Portside Wealth Group LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 41.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,016 shares of the healthcare product maker’s stock after selling 13,652 shares during the quarter. Portside Wealth Group LLC’s holdings in Abbott Laboratories were worth $2,382,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ABT. Lakeshore Capital Group Inc. lifted its stake in shares of Abbott Laboratories by 4.0% during the 4th quarter. Lakeshore Capital Group Inc. now owns 7,367 shares of the healthcare product maker’s stock valued at $923,000 after buying an additional 280 shares in the last quarter. Sound Income Strategies LLC lifted its stake in shares of Abbott Laboratories by 6.8% during the 4th quarter. Sound Income Strategies LLC now owns 2,130 shares of the healthcare product maker’s stock valued at $259,000 after buying an additional 135 shares in the last quarter. Rathbones Group PLC lifted its stake in shares of Abbott Laboratories by 3.6% during the 4th quarter. Rathbones Group PLC now owns 3,116,386 shares of the healthcare product maker’s stock valued at $390,452,000 after buying an additional 107,648 shares in the last quarter. Guild Investment Management Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $202,000. Finally, Buffalo Business & Estate Services Ltd. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $280,000. 75.18% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth C. Cushman sold 263 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the sale, the executive vice president owned 38,573 shares in the company, valued at $4,458,267.34. This represents a 0.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Citigroup lowered their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Leerink Partners lowered their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $135.68.

Abbott Laboratories Stock Down 0.6%

Shares of ABT stock opened at $102.30 on Tuesday. The stock has a market cap of $178.16 billion, a P/E ratio of 27.50, a PEG ratio of 1.64 and a beta of 0.79. Abbott Laboratories has a 52 week low of $100.88 and a 52 week high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The company’s fifty day simple moving average is $109.35 and its two-hundred day simple moving average is $120.71.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.